Samsrita Labs Limited operates as a biopharmaceutical company in India. It offers DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and prenatal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype, and fluorescence in-situ hybridization analysis. The company is also involved in the stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffold development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology for the body organs of the liver, pancreas, neural, cardiac, vascular, renal, and orthopedic systems. In addition, it engages in new drug discovery, targeting therapeutic areas, such as Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular disease, cystinosis, and Huntington's disease. Further, the company provides molecular prognosis and diagnostic services in the areas of cytogenetics, pharmacogenomics, pathology, radiology, hematology, biochemistry, microbiology, and others; and develops liver support devices, bioengineered implantable humanized nerve conduits, implantable nanochips carrying insulin-producing cells, and extracorporeal devices, as well as contract research and manufacturing services. Additionally, it offers molecular diagnostics services to patients, private consultants, academic and hospital services, hospitals, and other healthcare institutions. The company was formerly known as Dr. Habeebullah Life Sciences Limited and changed its name to Samsrita Labs Limited in October 2022. Samsrita Labs Limited was incorporated in 1996 and is based in Hyderabad, India.